• Large multinational pharmaceutical companies who have expertise in navigating the US regulatory and market environment and who have an interest in looking at trade agreements involving NZ healthcare procurement and more specifically the role of PHARMAC and IP.
NZ’s highly innovative devices, digital technology, pharmaceutical and diagnostic
companies whose products may be of direct interest to those companies.
The committee will meet quarterly, initially at the beginning of each year to come up with 2-3 issues the group would want to focus on and address. Results could be policy submissions and/or possible Doorknocks to Wellington. Topics could include: IP, Privacy, Procurement, Supply and Vaccine issues, Health Technology Assessment and de-identified health data.
Peter Kane, Committee Chair - Immunology Commercial Lead, Pfizer New Zealand Ltd